Upper-extremity deep vein thrombosis and chronic pulmonary embolism resulting in pulmonary artery hypertension.

1998 ◽  
Vol 170 (6) ◽  
pp. 1532-1534 ◽  
Author(s):  
M R Gomes ◽  
H Tomaso ◽  
G K Nazarian ◽  
H Bjarnason ◽  
C A Dietz ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Pulmonary Artery ◽  
Upper Extremity ◽  
Pulmonary Artery Hypertension ◽  
Vein Thrombosis ◽  
Chronic Pulmonary Embolism ◽  
Deep Vein

Postpartum cardiomyopathy complicated with upper-extremity deep vein thrombosis and pulmonary embolism

2011 ◽  
Vol 152 (3) ◽  
pp. e58-e60
Author(s):  
Ioannis Andreou ◽  
Christina Chrysohoou ◽  
Costas Tentolouris ◽  
Stefanos Archontakis ◽  
Stella Brili ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Upper Extremity ◽  
Vein Thrombosis ◽  
Postpartum Cardiomyopathy ◽  
Deep Vein

Antithrombin-III Deficiency Causing Deep Vein Thrombosis And Pulmonary Embolism In A Young Male

1981 ◽  
Author(s):  
K Genth ◽  
J Schaefer ◽  
J Frank ◽  
W Krämer ◽  
B Weinei ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Pulmonary Artery ◽  
Antithrombin Iii ◽  
Clinical Symptoms ◽  
Venous Pressure ◽  
Vein Thrombosis ◽  
At Iii ◽  
Antithrombin Iii Deficiency ◽  
Deep Vein

A 34 year old male was admitted to the hospital with typical clinical symptoms of acute pulmonary embolism caused by deep vein thrombosis in the upper leg detected by phlebography. Pulmonary embolism was verified by the lung-perfusion-scintigram. The patient developed an infarct pneumonia with hemoptoe. Episodic thromboembolic phenomena occurred due to antithrombin-III deficiency (AT-III). The method, using homogenic substrates exhibited low AT-III activity of 8.6 IU/ml(25°C) due to a familiar AT-III deficit. Fiberoptic pulmonary catheter was placed into the pulmonary artery to measure pulmonary artery pressure (PAP, PCP), right ventricular pressure (RVP) and to determine cardiac output (CO) using the dye dilution technique. Heart rate (HR), central venous pressure (CVP) and aortic pressure (AOP) were recorded continuously. Patient received immediately fibrinolytic therapy, initiated by an initial dose of streptokinase (SK)(250 000 IU/20 min.), followed by a maintenance dose (100 000 IU/h), lasting 3 days. M-mode echocardiography detected before SK a moderate enlarged right ventricle and a small left ventricle, indicating a low output. After SK these values were improved. In conclusion, this case demonstrated a serious thromboembolic disorder, related to AT-III deficit. SK-therapy improved the hemodynamic situation.

Upper Extremity Deep Vein Thrombosis Central Venous Catheters-Related and Pulmonary Embolism After Cardiac Surgery

CHEST Journal ◽  
2014 ◽  
Vol 145 (3) ◽  
pp. 527A
Author(s):  
Cleante Scarduelli ◽  
Redenta Ghirardi ◽  
Ornella Tortelli ◽  
Rino Frizzelli ◽  
Fabia Mascaro ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Cardiac Surgery ◽  
Deep Vein Thrombosis ◽  
Upper Extremity ◽  
Central Venous Catheters ◽  
Central Venous ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals Venous Thromboembolism Within Professional American Sport Leagues

2017 ◽  
Vol 5 (12) ◽  
pp. 232596711774553 ◽  
Author(s):  
Meghan Bishop ◽  
Matthew Astolfi ◽  
Eric Padegimas ◽  
Peter DeLuca ◽  
Sommer Hammoud
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Lower Extremity ◽  
Upper Extremity ◽  
Return To Play ◽  
Professional Athletes ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

Background: Numerous reports have described players in professional American sports leagues who have been sidelined with a deep vein thrombosis (DVT) or a pulmonary embolism (PE), but little is known about the clinical implications of these events in professional athletes. Purpose: To conduct a retrospective review of injury reports from the National Hockey League (NHL), Major League Baseball (MLB), the National Basketball Association (NBA), and the National Football League (NFL) to take a closer look at the incidence of DVT/PE, current treatment approaches, and estimated time to return to play in professional athletes. Study Design: Descriptive epidemiology study. Methods: An online search of all team injury and media reports of DVT/PE in NHL, MLB, NBA, and NFL players available for public record was conducted by use of Google, PubMed, and SPORTDiscus. Searches were conducted using the professional team name combined with blood clot, pulmonary embolism, and deep vein thrombosis. Results: A total of 55 venous thromboembolism (VTE) events were identified from 1999 through 2016 (NHL, n = 22; MLB, n = 16; NFL, n = 12; NBA, n = 5). Nineteen athletes were reported to have an upper extremity DVT, 15 had a lower extremity DVT, 15 had a PE, and 6 had DVT with PE. Six athletes sustained more than 1 VTE. The mean age at time of VTE was 29.3 years (range, 19-42 years). Mean (±SD) time lost from play was 6.7 ± 4.9 months (range, 3 days to career end). Seven athletes did not return to play. Players with upper extremity DVT had a faster return to play (mean ± SD, 4.3 ± 2.7 months) than those with lower extremity DVT (5.9 ± 3.8 months), PE (10.8 ± 6.8 months), or DVT with PE (8.2 ± 2.6 months) ( F = 5.69, P = .002). No significant difference was found regarding time of return to play between sports. Conclusion: VTE in professional athletes led to an average of 6.7 months lost from play. The majority of athletes were able to return to play after a period of anticoagulation or surgery. Those with an upper extremity DVT returned to play faster than those with other types of VTE. Further study is needed to look into modifiable risk factors for these events and to establish treatment and return-to-play guidelines to ensure the safety of these athletes.

Sign in / Sign up

Export Citation Format

Share Document